EPS for Hostess Brands, Inc. (TWNK) Expected At $0.19; Aratana Therapeutics (PETX) Had 5 Bulls

August 2, 2017 - By Henry Gaston

Among 6 analysts covering Aratana Therapeutics (NASDAQ:PETX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aratana Therapeutics had 10 analyst reports since July 29, 2015 according to SRatingsIntel. The company was initiated on Friday, August 19 by Jefferies. The company was maintained on Thursday, August 11 by Barclays Capital. Lake Street initiated the shares of PETX in report on Wednesday, July 29 with “Buy” rating. As per Thursday, February 4, the company rating was initiated by Credit Suisse. The stock of Aratana Therapeutics Inc (NASDAQ:PETX) earned “Buy” rating by Jefferies on Thursday, June 8. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, March 16 report. The firm has “Hold” rating by Craig Hallum given on Friday, September 25. See Aratana Therapeutics Inc (NASDAQ:PETX) latest ratings:

08/06/2017 Broker: Jefferies Rating: Buy New Target: $8.0000 Maintain

Analysts expect Hostess Brands, Inc. (NASDAQ:TWNK) to report $0.19 EPS on August, 8.They anticipate $0.37 EPS change or 205.56% from last quarter’s $-0.18 EPS. TWNK’s profit would be $18.99M giving it 19.62 P/E if the $0.19 EPS is correct. After having $0.15 EPS previously, Hostess Brands, Inc.’s analysts see 26.67% EPS growth. It closed at $14.91 lastly. It is down 69.90% since August 2, 2016 and is uptrending. It has outperformed by 53.20% the S&P500.

Among 4 analysts covering Hostess Brands (NASDAQ:TWNK), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Hostess Brands had 4 analyst reports since February 14, 2017 according to SRatingsIntel. The stock of Hostess Brands, Inc. (NASDAQ:TWNK) earned “Hold” rating by UBS on Monday, July 31. Deutsche Bank initiated it with “Buy” rating and $18 target in Wednesday, February 15 report.

Aratana Therapeutics, Inc. is a pet therapeutics firm focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The company has market cap of $281.45 million. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. It currently has negative earnings. The Company’s lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation , appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA).

Investors sentiment decreased to 0.71 in 2016 Q4. Its down 1.48, from 2.19 in 2016Q3. It turned negative, as 25 investors sold Aratana Therapeutics Inc shares while 37 reduced holdings. 12 funds opened positions while 32 raised stakes. 28.38 million shares or 0.36% less from 28.48 million shares in 2016Q3 were reported. Bank Of America De holds 0% or 8,306 shares. Sg Americas Securities Limited Liability reported 15,695 shares. Blackrock Institutional Trust Commerce Na holds 0% in Aratana Therapeutics Inc (NASDAQ:PETX) or 923,722 shares. 396,961 are owned by Principal Gru. Janus Lc accumulated 1.43M shares. Mpm Asset Mgmt Limited Liability Com holds 0.85% or 250,000 shares. State Street Corp invested 0% in Aratana Therapeutics Inc (NASDAQ:PETX). Blackrock reported 0% in Aratana Therapeutics Inc (NASDAQ:PETX). Savings Bank Of Montreal Can invested in 14,990 shares. Bnp Paribas Arbitrage Sa has invested 0% in Aratana Therapeutics Inc (NASDAQ:PETX). Acadian Asset Mgmt Limited Liability Com holds 0.02% in Aratana Therapeutics Inc (NASDAQ:PETX) or 501,166 shares. Tudor Investment Corporation Et Al holds 13,000 shares or 0% of its portfolio. 4,598 are owned by Tower Rech Capital Ltd Liability Company (Trc). Redmond Asset Llc has 0.18% invested in Aratana Therapeutics Inc (NASDAQ:PETX) for 53,887 shares. Goldman Sachs Gp invested in 60,250 shares.

It closed at $6.69 lastly. It is down 1.52% since August 2, 2016 and is uptrending. It has underperformed by 15.18% the S&P500.